Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Industry News

    Key Patent Awarded for Synthetic Saponin Vaccine Adjuvant

    By Global Biodefense StaffNovember 15, 2012
    Share
    Facebook LinkedIn Reddit Email

    The United States Patent and Trademark Office has granted the co-founders of Adjuvance Technologies, Inc., a patent for a pioneering invention which provides a novel synthetic method to produce saponin adjuvants including QS-21, a leading vaccine adjuvant currently used in advanced clinical trials for infectious disease, neurodegenerative disorders and oncology. 

    Despite the critical ability of adjuvants to improve the immune response to vaccine antigens, there are very few adjuvants approved for human use in the U.S. 

    One of the most widely used and potent immunological adjuvants is a mixture of soluble triterpene glycosides purified from the soap bark tree (Quillaja saponaria). Despite challenges in production, quality control, stability and toxicity, this extract exhibits exceptional adjuvant properties for a range of antigens. 

    Adjuvance’s new patented technology providing an ecologically sustainable synthetic product of the active molecules of QS-21 that is extremely dependable and scalable. This ability provides a robust method to produce this leading vaccine adjuvant in high purity as well as to produce novel synthetic QS-21 congeners designed to induce increased immune responsiveness and decreased toxicity. 

    “We believe this technology, which was developed at the Sloan-Kettering Institute of Memorial Sloan-Kettering Cancer Center, represents a fundamental breakthrough in vaccine adjuvant design and manufacturing,” said Jeffrey Gardner, Adjuvance Technologies‘ CEO and co-founder. “Before this innovative approach to producing saponin adjuvants, tedious isolation and purification protocols were necessary to obtain these materials. This work will greatly facilitate access to these promising molecules for investigators and vaccine developers.” 

    As exclusive licensee of the technology, Adjuvance will continue to focus on the commercial development of saponin adjuvants for use in innovative therapeutic and prophylactic human vaccines as well as pandemic preparedness and biodefense efforts.

    Awards Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBioterror Attacks, Surveillance and Social Media Analytics
    Next Article Nano-Bio Manufacturing Consortium

    Related Stories

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    NIAID Seeks to Improve Computational Models of Influenza Immunity

    September 15, 2023

    Smallpox Vaccines: Bavarian Nordic Awarded Another Contract to Supply EU Strategic Reserve

    September 13, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.